

# Phase 2 Study of Investigational Elranatamab (PF-06863135), a BCMA-CD3 Bispecific Antibody, as Monotherapy in Participants With Multiple Myeloma (MM) Who Are Refractory to at Least One Proteasome Inhibitor (PI), One Immunomodulatory Drug (IMiD), and One Anti-CD38 Monoclonal Antibody (mAb)<sup>1,2</sup>

MagnetisMM-3 is an open-label, multicenter, non-randomized Phase 2 study of elranatamab monotherapy in participants with MM who are refractory to at least one PI, one IMiD, and one anti-CD38 mAb.

Elranatamab is an investigational compound. These are not the complete inclusion/exclusion criteria. This information is current as of June 2021.

## KEY INCLUSION CRITERIA:

- MM diagnosis as defined according to International Myeloma Working Group (IMWG)
- Age ≥18 years
- Refractory to ≥1 IMiD, ≥1 PI, and ≥1 anti-CD38 mAb
- Relapsed/refractory to last anti-MM regimen
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2
- Adequate renal, hepatic, cardiac, and bone marrow function
- Cohort A: has not received prior B-cell maturation antigen (BCMA)-directed therapy
- Cohort B: has received prior BCMA-directed therapy (ADC or CAR-T-cells)

## KEY EXCLUSION CRITERIA:

- Smoldering MM
- Plasma cell leukemia
- Amyloidosis
- Active and clinically significant bacterial, fungal, or viral infection
- Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes (POEMS) syndrome
- Stem cell transplant within 12 weeks prior to enrollment

## PATIENT POPULATION (N=150):

- MM
- Refractory to:
  - ≥1 IMiD
  - ≥1 PI
  - ≥1 anti-CD38 mAb
- Patients are allowed other prior therapies

## COHORT A

No prior BCMA-directed therapy  
 elranatamab monotherapy subcutaneous (SC)

## COHORT B

Prior BCMA-directed antibody-drug conjugate (ADC) or chimeric antigen receptor (CAR)-T-cell therapy (no prior BCMA-directed bispecific antibody)  
 elranatamab monotherapy SC

## PRIMARY ENDPOINT:

- Objective response rate

## KEY SECONDARY ENDPOINTS:

- Duration of response
- Minimum residual disease (MRD) negativity rate
- Progression-free survival
- Safety
- Pharmacokinetics
- Immunogenicity

Learn more at [ClinicalTrials.gov](https://ClinicalTrials.gov)  
**NCT04649359**